Parnax Lab Ltd
Parnax Lab Ltd (PARNAXLAB) last reported results for the quarter ended Jun 2026, with sales of ₹56.8 crore and net profit of ₹0.43 crore. The stock last traded at ₹115, a market capitalisation of ₹133 crore, on a P/E of 13.2. Over the past 52 weeks the stock has ranged between ₹99.2 and ₹182. Figures are as of 9 Oct 2026 and are not real time.
Parnax Lab Ltd share price and key metrics
- Current price
- ₹115
- Market cap
- ₹133 cr
- Stock P/E
- 13.2
- Book value
- ₹82.8
- ROE
- 14.2%
- ROCE
- 13.8%
- Dividend yield
- 0.00%
- 52w high / low
- 182/99.2
Metrics as of 9 Oct 2026. Not real time.
Track Parnax Lab Ltd
Cruxal reads every Parnax Lab Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Parnax Lab Ltd growth and returns
- 10 Years
- 13%
- 5 Years
- 23%
- 3 Years
- 14%
- TTM
- 32%
- 10 Years
- 18%
- 5 Years
- 105%
- 3 Years
- 14%
- TTM
- -7%
- 10 Years
- 12%
- 5 Years
- 34%
- 3 Years
- 6%
- 1 Year
- -12%
- 10 Years
- 11%
- 5 Years
- 15%
- 3 Years
- 15%
- Last Year
- 14%
Parnax Lab Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹56.8 cr, up 6.4% from ₹53.38 cr a year earlier. Net profit was ₹0.43 cr, down 86.9% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 48.36 | 40.22 | 49.04 | 53.38 | 62.6 | 62.94 | 69.63 | 56.8 |
| Expenses | 41.12 | 35.95 | 42.41 | 45.94 | 54.52 | 56.09 | 64.75 | 52.49 |
| Operating profit | 7.24 | 4.27 | 6.63 | 7.44 | 8.08 | 6.85 | 4.88 | 4.31 |
| OPM % | 14.97% | 10.62% | 13.52% | 13.94% | 12.91% | 10.88% | 7.01% | 7.59% |
| Other income | 0.95 | 0.19 | 0.43 | 0.18 | 0.63 | -0.17 | 1.76 | 0.15 |
| Interest | 1.38 | 1.23 | 1.28 | 1.22 | 1.4 | 1.47 | 1.61 | 1.64 |
| Depreciation | 1.94 | 1.79 | 1.83 | 1.94 | 2.1 | 1.96 | 2.04 | 2.22 |
| Profit before tax | 4.87 | 1.44 | 3.95 | 4.46 | 5.21 | 3.25 | 2.99 | 0.6 |
| Tax % | 29.77% | 16.67% | 26.08% | 26.46% | 30.33% | 16.62% | 27.09% | 28.33% |
| Net profit | 3.42 | 1.21 | 2.93 | 3.28 | 3.62 | 2.71 | 2.19 | 0.43 |
| EPS (₹) | 2.97 | 1.05 | 2.54 | 2.85 | 3.16 | 2.36 | 1.90 | 0.37 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Parnax Lab Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 95 | 106 | 109 | 95 | 90 | 163 | 168 | 189 | 188 | 249 | 252 |
| Operating profit | 13 | 10 | 10 | 6 | 10 | 23 | 23 | 24 | 27 | 27 | 24 |
| OPM % | 14% | 10% | 9% | 7% | 11% | 14% | 14% | 12% | 14% | 11% | 10% |
| Net profit | 4 | 1 | 3 | -3 | -0 | 8 | 9 | 10 | 12 | 12 | 9 |
| EPS (₹) | 4.33 | 1.23 | 3.88 | -3.42 | -0.42 | 8.40 | 7.51 | 8.37 | 10.03 | 10.26 | 7.79 |
TTM is the trailing twelve months to the most recent quarter.
Parnax Lab Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 8 | 8 | 8 | 8 | 8 | 10 | 11 | 11 | 11 | 11 |
| Reserves | 23 | 24 | 27 | 24 | 24 | 38 | 51 | 60 | 72 | 84 |
| Borrowings | 39 | 37 | 42 | 51 | 59 | 69 | 55 | 81 | 70 | 83 |
| Other liabilities | 15 | 18 | 17 | 23 | 15 | 36 | 28 | 38 | 37 | 50 |
| Total liabilities | 86 | 87 | 95 | 107 | 106 | 153 | 145 | 190 | 190 | 228 |
| Fixed assets | 47 | 44 | 51 | 58 | 60 | 72 | 77 | 89 | 88 | 115 |
| CWIP | 0 | 0 | 0 | 3 | 5 | 3 | 2 | 21 | 29 | 11 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other assets | 38 | 43 | 43 | 46 | 41 | 78 | 66 | 80 | 72 | 101 |
| Total assets | 86 | 87 | 95 | 107 | 106 | 153 | 145 | 190 | 190 | 228 |
As reported by the company. Total assets equal total liabilities by construction.
Parnax Lab Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 16 | 13 | 9 | 9 | 6 | 9 | 21 | 16 | 32 | 8 |
| Cash from investing | -10 | -5 | -11 | -13 | -7 | -16 | -10 | -32 | -16 | -16 |
| Cash from financing | -5 | -7 | 1 | 5 | 0 | 12 | -14 | 15 | -16 | 8 |
| Net cash flow | 0 | 1 | -1 | 0 | -0 | 4 | -3 | -1 | 0 | -0 |
| Free cash flow | 5 | 8 | -3 | -4 | -0 | -8 | 11 | -16 | 16 | -9 |
| CFO / operating profit | 134% | 134% | 99% | 153% | 71% | 38% | 103% | 79% | 130% | 42% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Parnax Lab Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 14% | 11% | 12% | 3% | 6% | 17% | 15% | 13% | 14% | 14% |
| Debtor days | 72 | 65 | 64 | 88 | 68 | 85 | 61 | 63 | 60 | 56 |
| Inventory days | 50 | 45 | 52 | 76 | 80 | 73 | 79 | 94 | 87 | 82 |
| Days payable | 48 | 45 | 44 | 74 | 46 | 81 | 53 | 74 | 72 | 73 |
| Cash conversion cycle | 74 | 64 | 72 | 90 | 102 | 77 | 86 | 83 | 75 | 65 |
| Working capital days | -26 | -8 | 0 | -31 | -66 | -35 | -19 | -23 | -24 | -11 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Parnax Lab Ltd shareholding pattern
Promoters held 72.30% at Jun 2026, broadly unchanged since Jun 2025.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 72.30% | 72.30% | 72.30% | 72.30% | 72.30% | 72.30% | 72.30% | 72.30% |
| Public | 27.71% | 27.71% | 27.70% | 27.70% | 27.71% | 27.70% | 27.71% | 27.71% |
| No. of shareholders | 4,173 | 4,521 | 4,440 | 4,317 | 4,111 | 3,900 | 3,721 | 3,572 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Parnax Lab Ltd corporate filings
- Company Conducts Annual General Meeting (AGM) with 100% approval for key resolutions including financial statements, appointment of auditors, director reappointment, and related party transactionsAGM/EGMlow impact
Cruxal's analysis: Parnax Lab Limited held its 44th AGM on 29th September 2026 via video conferencing, with…
Read the full analysis - Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/sCompany Updatemedium impact
- Shareholder Meeting / Postal Ballot-Outcome of AGMAGM/EGMmedium impact
- Closure of Trading Window for the Quarter and Half Year Ended September, 2026Insider Trading / SASTlow impact
- Parnax Lab Limited announces 44th Annual General Meeting (AGM) scheduled for September 29, 2026Company Updatelow impact
Cruxal's analysis: Parnax Lab Limited has issued a formal notice for its 44th Annual General Meeting to be…
Read the full analysis - Parnax Lab Limited Announces 44th AGM and Seeks Shareholder Approval for Material Related Party TransactionsAGM/EGMlow impact
Cruxal's analysis: Parnax Lab Limited has issued a notice for its 44th Annual General Meeting scheduled for…
Read the full analysis - Parnax Lab Ltd releases Annual Report for the financial year ended March 31, 2026Otherslow impact
Cruxal's analysis: Parnax Lab Ltd has filed its Annual Report for the fiscal year ended March 31, 2026, in…
Read the full analysis - Parnax Lab Ltd. Announces Book Closure and Record Date for 44th Annual General MeetingCorp. Actionlow impact
Cruxal's analysis: Parnax Lab Ltd. has issued a formal notice regarding the closure of its Register of…
Read the full analysis - Parnax Lab Limited approves revised Directors Report for FY 2025-26Otherslow impact
Cruxal's analysis: Parnax Lab Limited has announced the approval of its revised Directors Report and the…
Read the full analysis - Parnax Lab Limited Reports Q1 FY2027 Financial Results and Announces Change in Statutory AuditorsBoard Meetinghigh impact
Cruxal's analysis: Parnax Lab Limited has released its unaudited standalone and consolidated financial…
Read the full analysis - Parnax Lab Limited: Promoter Group Executes Inter-se Transfer of 3.77 Lakh Equity SharesInsider Trading / SASTlow impact
Cruxal's analysis: Parnax Lab Limited has disclosed an inter-se transfer of 3.77 lakh equity shares…
Read the full analysis - Parnax Lab Limited: Promoter Group Executes Inter-se Transfer of Shares via GiftInsider Trading / SASTlow impact
Cruxal's analysis: Parnax Lab Limited has disclosed an off-market inter-se transfer of 3.61 lakh equity…
Read the full analysis - Parnax Lab Limited: Promoter Group completes inter-se transfer of 3.62 lakh equity shares via giftInsider Trading / SASTlow impact
Cruxal's analysis: Parnax Lab Limited has disclosed an inter-se transfer of 3,61,872 equity shares…
Read the full analysis - Parnax Lab Limited: Promoter Group Executes Inter-se Transfer of 3.77 Lakh Equity SharesInsider Trading / SASTlow impact
Cruxal's analysis: Parnax Lab Limited has disclosed an inter-se transfer of 3.77 lakh equity shares…
Read the full analysis - Parnax Lab Limited announces successful re-appointment of Independent Director via postal ballotAGM/EGMlow impact
Cruxal's analysis: Parnax Lab Limited has successfully concluded its postal ballot process, with…
Read the full analysis - Parnax Lab Ltd. Announces Re-appointment of Independent Director Yogesh Kantilal VariaAGM/EGMlow impact
Cruxal's analysis: Parnax Lab Ltd. has formally announced the re-appointment of Mr. Yogesh Kantilal Varia as…
Read the full analysis - Parnax Lab Limited schedules Board Meeting for August 14, 2026, to approve Q1 FY27 financial resultsBoard Meetinglow impact
Cruxal's analysis: Parnax Lab Limited has issued a formal notice for a Board of Directors meeting scheduled…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.